Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel T Connolly

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|July 25, 2009
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biologyJohn W Adams, Juan Ramirez, Yunqing Shi, et al.
Journal of Clinical Lipidology|February 5, 2011
Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humansEseng Lai, M Gerard Waters, James R Tata, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109aPhilip J Skinner, Martin C Cherrier, Peter J Webb, et al.
The Journal of Biological Chemistry|April 25, 2007
Nicotinic acid receptor agonists differentially activate downstream effectorsJeremy G Richman, Martha Kanemitsu-Parks, Ibragim Gaidarov, et al.
Journal of Medicinal Chemistry|May 16, 2003
Discovery of a simple picomolar inhibitor of cholesteryl ester transfer proteinEmily J Reinhard, Jane L Wang, Richard C Durley, et al.
Journal of Medicinal Chemistry|May 12, 2010
Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosisYifeng Xiong, Bradley R Teegarden, Jin-Sun Karoline Choi, et al.
Journal of Medicinal Chemistry|August 23, 2002
Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer proteinRichard C Durley, Margaret L Grapperhaus, Brian S Hickory, et al.
Journal of Medicinal Chemistry|July 31, 2008
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in miceGraeme Semple, Philip J Skinner, Tawfik Gharbaoui, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2007
Agonist lead identification for the high affinity niacin receptor GPR109aTawfik Gharbaoui, Philip J Skinner, Young-Jun Shin, et al.
Journal of Medicinal Chemistry|March 23, 2012
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humansP Douglas Boatman, Brett Lauring, Thomas O Schrader, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Pharmacology and Experimental Therapeutics|July 25, 2009
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biologyJohn W Adams, Juan Ramirez, Yunqing Shi, et al.
Journal of Clinical Lipidology|February 5, 2011
Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humansEseng Lai, M Gerard Waters, James R Tata, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109aPhilip J Skinner, Martin C Cherrier, Peter J Webb, et al.
The Journal of Biological Chemistry|April 25, 2007
Nicotinic acid receptor agonists differentially activate downstream effectorsJeremy G Richman, Martha Kanemitsu-Parks, Ibragim Gaidarov, et al.
Journal of Medicinal Chemistry|May 16, 2003
Discovery of a simple picomolar inhibitor of cholesteryl ester transfer proteinEmily J Reinhard, Jane L Wang, Richard C Durley, et al.
Journal of Medicinal Chemistry|May 12, 2010
Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosisYifeng Xiong, Bradley R Teegarden, Jin-Sun Karoline Choi, et al.
Journal of Medicinal Chemistry|August 23, 2002
Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer proteinRichard C Durley, Margaret L Grapperhaus, Brian S Hickory, et al.
Journal of Medicinal Chemistry|July 31, 2008
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in miceGraeme Semple, Philip J Skinner, Tawfik Gharbaoui, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2007
Agonist lead identification for the high affinity niacin receptor GPR109aTawfik Gharbaoui, Philip J Skinner, Young-Jun Shin, et al.
Journal of Medicinal Chemistry|March 23, 2012
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humansP Douglas Boatman, Brett Lauring, Thomas O Schrader, et al.
Pageof 3